by The global Next generation cancer diagnostics market size was estimated to be around US$ 15.2 billion in 2022. It is projected to reach US$ 32.9 billion by 2032, indicating a CAGR of 8.02% from 2023 to 2032.
Key Takeaways
- By technology, next-generation sequencing accounted highest revenue share of around 37.1% in 2022.
- By application, the biomarker development segment has held the largest revenue share of around 40.8% in 2022.
- By application, the genetic analysis segment is expanding at a CAGR of 11.2% over the forecast period 2023 to 2032.
- By cancer type, breast cancer is expected to grow at a CAGR of 10.1% over the forecast period.
- By function, the therapeutic monitoring segment has dominated the market with a revenue share of 26% in 2022 whereas the prognostic diagnostics segment is expected to reach a CAGR of 10.2% during the forecast period.
- By region, North America accounted largest revenue share of 40.7% in 2022.
- The Asia Pacific region is poised to grow at a CAGR of 12.1% over the forecast period.
The market research report on the Next generation cancer diagnostics market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Next generation cancer diagnostics products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3246
Report Scope of the Next Generation Cancer Diagnostics Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 16.42 Billion |
| Market Size by 2032 | USD 32.9 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.02% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Technology, By Application, By Cancer Type, and By Function |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Hydraulic Tools and Equipment Market Size to Garner USD 71.33 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Next generation cancer diagnostics market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Next generation cancer diagnostics market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Next generation cancer diagnostics products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Next generation cancer diagnostics market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Next generation cancer diagnostics market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Next generation cancer diagnostics market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Key Market Players:
- GE HealthCare
- Koninklijke Philips N.V.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc. (Dako)
- Abbott
- Thermo Fisher Scientific Inc.
- Janssen Pharmaceuticals, Inc.
Segments Covered in the Report:
By Technology
- Next-generation Sequencing
- Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
- qPCR & Multiplexing
- Protein Microarrays
- DNA Microarrays
By Application
- Biomarker Development
- Proteomic Analysis
- CTC Analysis
- Epigenetic Analysis
- Genetic Analysis
By Cancer Type
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Cervical Cancer
- Others
By Function
- Therapeutic Monitoring
- Prognostics
- Companion Diagnostics
- Cancer Screening
- Risk Analysis
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Next Generation Cancer Diagnostics Market
5.1. COVID-19 Landscape: Next Generation Cancer Diagnostics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Next Generation Cancer Diagnostics Market, By Technology
8.1. Next Generation Cancer Diagnostics Market, by Technology, 2023-2032
8.1.1. Next-generation Sequencing
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Lab-on-a-chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. qPCR & Multiplexing
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Protein Microarrays
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. DNA Microarrays
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Next Generation Cancer Diagnostics Market, By Application
9.1. Next Generation Cancer Diagnostics Market, by Application, 2023-2032
9.1.1. Biomarker Development
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Proteomic Analysis
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. CTC Analysis
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Epigenetic Analysis
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Genetic Analysis
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Next Generation Cancer Diagnostics Market, By Cancer Type
10.1. Next Generation Cancer Diagnostics Market, by Cancer Type, 2023-2032
10.1.1. Lung Cancer
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Breast Cancer
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Cervical Cancer
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Next Generation Cancer Diagnostics Market, By Function
11.1. Next Generation Cancer Diagnostics Market, by Function, 2023-2032
11.1.1. Therapeutic Monitoring
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Prognostics
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Companion Diagnostics
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Cancer Screening
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Risk Analysis
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Next Generation Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.4. Market Revenue and Forecast, by Function (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Function (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.4. Market Revenue and Forecast, by Function (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Function (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Function (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Function (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.4. Market Revenue and Forecast, by Function (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Function (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Function (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Function (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.4. Market Revenue and Forecast, by Function (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Function (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Function (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Function (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Function (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Function (2020-2032)
Chapter 13. Company Profiles
13.1. GE HealthCare
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Koninklijke Philips N.V.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Illumina, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Agilent Technologies, Inc. (Dako)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Thermo Fisher Scientific Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Janssen Pharmaceuticals, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
